StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

Research analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

Shares of ONVO opened at $1.66 on Friday. The firm has a market capitalization of $2.82 million, a price-to-earnings ratio of -1.95 and a beta of 1.13. Organovo has a 52 week low of $1.62 and a 52 week high of $21.96. The business’s fifty day moving average price is $4.39 and its two-hundred day moving average price is $4.76.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. As a group, research analysts forecast that Organovo will post -0.77 EPS for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.